Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
Last Updated 2 October 2014 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…
With a large and growing patient population, asthma is one of the most lucrative drug markets in the pharmaceutical industry. Maintenance treatments for persistent asthma include inhaled…
Last Updated 1 October 2014 The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer compelling commercial opportunities driven by considerable unmet need. The AD population…
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…
Last Updated 29 September 2014 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…
Recent changes in the US healthcare system are having a profound and transformational impact on the medical technology industry. As manufacturers face challenges to the traditional business model…
Last Updated 29 September 2014 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly, and its prevalence is expected to grow 2% annually as the…
Heart failure describes a pathophysiological state in which the heart is unable to efficiently supply the body with oxygenated blood in order to meet the body’s metabolic demands. While acute…
With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their…
The financial burden of providing healthcare and the rising cost of the most innovative medicines have pressured government healthcare budgets and highlight the need for payers to operate under a…
TreatmentTrends®: Rheumatoid Arthritis 2014 (US) explores the use of conventional DMARDs as well as biologics or Xeljanz for the treatment of rheumatoid arthritis (RA). One hundred U.S…
The asthma market has historically been one of the most lucrative drug markets in the pharmaceutical industry owing to a large and growing patient population. However, generic and/or branded-…
Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…
Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…
